Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Accumulated Expenses (2019 - 2025)

Historic Accumulated Expenses for aTYR PHARMA (ATYR) over the last 7 years, with Q3 2025 value amounting to $10.2 million.

  • aTYR PHARMA's Accumulated Expenses rose 1369.73% to $10.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.2 million, marking a year-over-year increase of 1369.73%. This contributed to the annual value of $9.4 million for FY2024, which is 1874.73% down from last year.
  • Latest data reveals that aTYR PHARMA reported Accumulated Expenses of $10.2 million as of Q3 2025, which was up 1369.73% from $10.3 million recorded in Q2 2025.
  • In the past 5 years, aTYR PHARMA's Accumulated Expenses registered a high of $11.6 million during Q4 2023, and its lowest value of $2.4 million during Q1 2021.
  • Its 5-year average for Accumulated Expenses is $7.8 million, with a median of $9.0 million in 2024.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first soared by 14642.68% in 2022, then plummeted by 2098.49% in 2025.
  • aTYR PHARMA's Accumulated Expenses (Quarter) stood at $4.0 million in 2021, then surged by 146.43% to $9.9 million in 2022, then increased by 17.21% to $11.6 million in 2023, then dropped by 18.75% to $9.4 million in 2024, then rose by 8.44% to $10.2 million in 2025.
  • Its last three reported values are $10.2 million in Q3 2025, $10.3 million for Q2 2025, and $7.9 million during Q1 2025.